CST3 and insomnia measurement: These authors hypothesized that CBT-I would have benefits on early markers of cardiovascular diseases (i.e., diastolic blood pressure, heart rate, HRV, C-reactive protein, N-terminal pro-brain natriuretic peptide and cystatin C) among patients diagnosed with insomnia, but the results of this clinical trial did not support that idea.